Long-term registry of adults with atrial fibrillation in China
Follows adults with atrial fibrillation in China to record their care and outcomes over time.
Plain-language title generated from the registry record
Registry title: Chinese Atrial Fibrillation Registry
Key facts
- Where
- Beijing and Hangzhou, ChinaSee the 2 sites
Where in China
- Beijing Anzhen HospitalBeijing, ChinaTaking people
- Sir Run Run Shaw Hospital Zhejiang University School of MedicineHangzhou, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Beijing Anzhen Hospital
- Trial code
- NCT06987825
- Record updated
- 23 May 2025
- Original description
This prospective, observational cohort study aims to establish a long-term registry of adult patients with atrial fibrillation (AF) in China to comprehensively characterize patient profiles and evaluate real-world management and outcomes over time. The objectives of the study are to:Read full original descriptionShow less
Chinese Atrial Fibrillation Registry
This prospective, observational cohort study aims to establish a long-term registry of adult patients with atrial fibrillation (AF) in China to comprehensively characterize patient profiles and evaluate real-world management and outcomes over time. The objectives of the study are to:
* Describe the demographic, clinical, and treatment characteristics of AF patients across different stages of disease progression. * Assess the effectiveness and safety of various AF treatment strategies, including oral anticoagulation, catheter ablation, and left atrial appendage closure, in routine clinical practice. * Identify patient- and treatment-related factors that influence therapeutic outcomes. * Explore the role of advanced technologies and artificial intelligence in improving procedural performance, risk stratification, and clinical decision-making in AF care.
Participants will undergo standardized baseline evaluation and longitudinal follow-up to collect data on heart rhythm monitoring, treatment exposures, healthcare utilization, clinical events, and patient-reported outcomes. This cohort will generate real-world evidence to inform personalized and evidence-based management of AF.
Inclusion: Age ≥ 18 years; Documented atrial fibrillation episode lasting >30 seconds confirmed by electrocardiogram (ECG), Holter monitor, implantable cardiac monitor, or wearable ECG device; Signed informed consent and willingness to participate in follow-up.
Exclusion: Presence of comorbid conditions associated with an expected life expectancy of less than 1 year; Atrial fibrillation due to a reversible cause (e.g., transient secondary AF).